Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers
Christina J. Bathgate, Emily F. Muther, Anna M. Georgiopoulos, et al.
Pediatric Pulmonology (2023) Vol. 58, Iss. 9, pp. 2469-2477
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Standards for the care of people with cystic fibrosis; establishing and maintaining health
Kevin W Southern, C. Addy, Scott C. Bell, et al.
Journal of Cystic Fibrosis (2023) Vol. 23, Iss. 1, pp. 12-28
Open Access | Times Cited: 43
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events
Bonnie W. Ramsey, Christoph U. Correll, David R. DeMaso, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 209, Iss. 3, pp. 299-306
Open Access | Times Cited: 29
Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort
Michael B. VanElzakker, Emma M. Tillman, Lael M. Yonker, et al.
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 6, pp. 603-609
Open Access | Times Cited: 25
Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPID
Deanna Green, Thomas Lahiri, Karen S. Raraigh, et al.
PEDIATRICS (2024) Vol. 153, Iss. 5
Closed Access | Times Cited: 14
Cystic fibrosis foundation position paper: Redefining the cystic fibrosis care team
Rebekah F. Brown, Charlotte T Close, Molly G Mailes, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 11
Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor
Sonia Graziano, Francesca Boldrini, Gaia Romana Pellicano, et al.
CHEST Journal (2023) Vol. 165, Iss. 4, pp. 800-809
Closed Access | Times Cited: 15
Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis
Aricca D. Van Citters, Enid Aliaj, Jessica A. Alvarez, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 6
Mental disorders in patients with cystic fibrosis
A. Klimenko, A Aleksandrova
The Clinician (2025) Vol. 18, Iss. 4, pp. 12-19
Open Access
Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve
Maggie Harrigan, Anna M. Georgiopoulos, Alexandra L. Quittner, et al.
BMJ Open Respiratory Research (2025) Vol. 12, Iss. 1, pp. e002606-e002606
Open Access
Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
Marta Solís García, Adrián Pelaez, Rosa Mar Gómez-Punter, et al.
BMC Pulmonary Medicine (2025) Vol. 25, Iss. 1
Open Access
The Dutch Gastrointestinal Symptom Tracker for People With Cystic Fibrosis: Associations With Anxiety, Depression, and Health‐Related Quality of Life
Marieke Verkleij, Berber Vlieg‐Boerstra, G.H. Hofsteenge, et al.
Pediatric Pulmonology (2025) Vol. 60, Iss. 3
Open Access
Cystic fibrosis year in review 2023
David V. Swetland, Adrienne P. Savant
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3106-3116
Open Access | Times Cited: 3
Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies
Jacob O'Connor, D. Nazareth, Dennis Wat, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 3
Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group
Christina J. Bathgate, David A. Fedele, Emma M. Tillman, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 3
Analysis of Depression and Anxiety Scores Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Adults With Cystic Fibrosis
Harish Pudukodu, Margret Z. Powell, Agathe Ceppe, et al.
The Clinical Respiratory Journal (2024) Vol. 18, Iss. 9
Open Access | Times Cited: 2
Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis
Tim W. R. Lee, Alistair Duff
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 209, Iss. 3, pp. 239-241
Open Access | Times Cited: 6
Continuously producible aztreonam-loaded inhalable lipid nanoparticles for cystic fibrosis-associated Pseudomonas aeruginosa infections – Development and in-vitro characterization
Gautam Chauhan, Abdul A. Shaik, Shruti S. Sawant, et al.
Biomaterials Advances (2024) Vol. 166, pp. 214027-214027
Closed Access | Times Cited: 1
What does it mean to be “healthy” when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study
Robin S. Everhart, Emma McWilliams, Jill Maggs, et al.
Journal of Cystic Fibrosis (2024)
Closed Access | Times Cited: 1
Spanish adaptation and validation of the child‐ and parent‐report cystic fibrosis questionnaire‐revised (CFQ‐R)
Paula Blanco‐Orive, Tamara del Corral, Patricia Martín–Casas, et al.
Pediatric Pulmonology (2023) Vol. 58, Iss. 12, pp. 3447-3457
Open Access | Times Cited: 2
Rethinking CF organization of care in the era of highly effective modulator: a nationwide research program HORIZON
Julie Haesaebert, Quitterie Reynaud, I. Durieu, et al.
Research Square (Research Square) (2024)
Open Access
EPS10.09 Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: comparison of healthcare providers’ observations in Europe vs US
Silvia Graziano, E.C. Landau, Horst Mitmansgruber, et al.
Journal of Cystic Fibrosis (2024) Vol. 23, pp. S65-S65
Closed Access
Mood Swings and Irritability in a Patient With Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor Therapy
Yu-Tung Lan, Yu-Ting Wung
Journal of Clinical Psychopharmacology (2024) Vol. 44, Iss. 5, pp. 528-530
Closed Access
Unveiling the Psychosocial Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis Patients
Marta Solís García, Adrián Pelaez, Rosa Mar Gómez Punter, et al.
Research Square (Research Square) (2024)
Closed Access
Fatty acid abnormalities in cystic fibrosis –the missing link for a cure?
Slawomira Drzymała-Czyż, Jarosław Walkowiak, Carla Colombo, et al.
iScience (2024) Vol. 27, Iss. 11, pp. 111153-111153
Closed Access
CFTR structures bound to ETI components predict rare mutation response to modulator combinations
Noemie Stanleigh, Michal Gur, Michal Shteinberg, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top